June 20, 2021 ~ TrialSite News ~
State of Goa Pulls Ivermectin from Home Medical Kits on Orders from Union Health Ministry
TrialSite recently reported that despite apparent success with the national ivermectin protocol in India—such as a dramatic turnaround of cases in Uttar Pradesh—the World Health Organization (WHO) itself highlighted, the Union Health Ministry and Family Welfare’s directorate general of health services known as DHS changed the guidelines again to cease use of Ivermectin and Doxycycline for COVID-19 treatment, dropping all medicines except for antipyretic and antitussives for asymptomatic and mild cases. This ruling, as a ripple effect now in the state of Goa where the directorate of health services (DHS), declared to all health centers and hospitals in this state to proceed with removing ivermectin, zinc, and doxycycline from the home medical kits given to COVID-19 patients, those in home isolation. There is substantial real-world data that at least in Uttar Pradesh, there’s been great success but TrialSite suspects a combination of pressure from WHO, industry, perhaps other government, and internal Indian strife leads to the removal of an approach that’s had a positive impact.
Posted recently in the Times of India, the center received the national authority communication just on Friday and, “The stock of the tablets taken out from the COVID kits will be returned to DHS.” Apparently, there are reports that at least half of the people involved suspected that two tablets in the kit failed to deter the virus. Yet, again, there’s considerable evidence from reports in Uttar Pradesh that these home kits made a world of difference. As TrialSite reported, even the WHO touted the effort of public health in Uttar Pradesh yet failed to mention the medication in the actual kits—ivermectin.
Suffice it to say, the Indian government has been aware of some benefit of ivermectin otherwise they wouldn’t have declared it on the national protocol. TrialSite has reports from various countries that WHO funds could be used as leverage for any and all that proposed the use of ivermectin. These claims cannot be substantiated but there’s been at least five contacts in different countries that have shared this point.
Of course, ivermectin isn’t authorized or recommended by leading regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the indication of COVID-19, and enormous sums are now generated for not only vaccines but also medications such as Remdesivir that are only somewhat effective and, according to the WHO itself, not effective against COVID-19. Important studies in the U.S. include the COVID-Out study led by University of Minnesota and funded by UnitedHealthcare. This study has the design, stature, and size that could, assuming positive results would lead to acceptance in the United States, which would reverberate with other regulatory bodies around the world.
TrialSite is on the record that “Regulatory Capture” has influenced what treatments get expedited review during this COVID-19 pandemic. The importance and final answers here will only come, over time, prompted by more intense interest from civil society as a whole.